MedTrace Logo

A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber

NCT04176185 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-06-30

No results posted yet for this study

Summary

This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR. The efficacy is evaluated using an environmental exposure chamber (EEC). Subjects will be randomised to receive treatment with HDM SLIT-tablet and placebo 1:1.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

Sublingual allergy immunological tablet

For daily administration (1 tablet per day)

OTHER

Placebo

For daily administration (1 tablet per day)

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Luo Zhang, Prof. · Beijing Tongren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2019-12-17
Completion
2022-01-19

Countries

  • Austria
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176185 on ClinicalTrials.gov